This bill establishes a prohibition on the procurement of opioid antidotes from certain pharmaceutical manufacturers and distributors that have been involved in settlements with state governments related to the opioid epidemic. Specifically, it mandates that the Division of Purchase and Property in the Department of the Treasury, or any State agency authorized to contract for goods or services, can only issue requests for proposals for opioid antidotes to entities that have not participated in such settlements. Any entity that has been a party to a settlement, including its affiliates or subsidiaries, will be barred from participating in the solicitation process.

Furthermore, the bill stipulates that once a request for proposal is awarded, the division or relevant State agency can only purchase opioid antidotes from the selected vendors that meet the criteria of not having been involved in any settlements related to the opioid epidemic. However, entities that entered into settlements prior to September 1, 2024, which included provisions to supply opioid antidotes, are allowed to continue fulfilling those obligations until they are completed. This legislation aims to ensure that the State's procurement of opioid antidotes is conducted in a manner that does not support companies that contributed to the opioid crisis.